Published on 10/12/2025

Fluids & Solvents: Choosing Realistic Simulants for SUS

The pharmaceutical industry faces numerous challenges concerning extractables and leachables (E&L) when utilizing single-use systems (SUS). Selecting realistic simulants for fluids and solvents is instrumental in conducting thorough E&L risk assessments, ensuring patient safety, and maintaining compliance with regulatory standards set forth by authorities such as the FDA, EMA, and MHRA. This guide provides a comprehensive step-by-step tutorial on selecting appropriate simulants for fluids and solvents in SUS, including considerations for container closure integrity and analytical evaluation thresholds.

Understanding Extractables and Leachables (E&L)

Extractables and leachables (E&L) refer to the substances that can be extracted from packaging or container systems into the drug product or its environment. By nature, these compounds may have significant implications on the safety and efficacy of pharmaceuticals. As per the Pharmaceutical Quality Research Institute (PQRI), performing a detailed E&L risk assessment is crucial for both compliance and patient safety.

Extractables are the substances released into a solvent during lab testing, mimicking the product’s chemistries and conditions, whereas leachables are those compounds that migrate into the drug product during storage and use. The correct selection of solvents is essential to adequately simulate real-world conditions for both extractables and leachables. Understanding the differences between extractables and leachables lays the foundation for evaluating and ensuring the container’s suitability for drug formulation.

Regulatory Expectations for E&L

Authorities such as the FDA, EMA, and MHRA mandate that pharmaceutical companies perform rigorous testing of E&L. The FDA guidance outlines that pharmaceutical manufacturers must demonstrate that E&L from SUS do not pose risks to patients. This aligns closely with ISO and ICH guidelines related to chemical contaminants in pharmaceuticals.

As regulations evolve, such as those highlighted in EU GMP Annex 1 on sterile drug production, the emphasis on E&L testing continues to grow. Demonstrating compliance necessitates a robust strategy encompassing thorough analytical evaluations and validation procedures.

Criteria for Selecting Realistic Simulants

When determining which simulants to use for E&L testing, several criteria must be evaluated to ensure that the chosen solvents and fluids provide realistic and representative data. The main factors include the nature of the drug product, the targeted administration route, and the storage conditions. Here are critical steps in the selection process:

• Identify the Drug Product: Understand the chemical and physical properties of the drug product to select simulants that accurately reflect its characteristics.
• Define Use Conditions: Determine how the product will interact with the plastic materials, including temperature, time, and pressure, which can influence leachables.
• Review Historical Data: Assess historical E&L data from similar products or materials to guide the selection of simulants based on prior findings.
• Consult Regulatory Guidelines: Refer to the latest guidelines from regulatory bodies such as the ICH whose mandate includes standards on E&L testing to ensure compliance.

Common Solvents Used as Simulants

A variety of solvents are used as simulants in E&L testing. Commonly utilized solvents include:

• Water: Given that many pharmaceuticals are aqueous-based, water is often used as the primary solvent.
• 1% Acetic Acid: This solvent is frequently employed for assessing extractables from packaging materials mimicking certain bulk formulations.
• Alcohols: Ethanol and isopropyl alcohol regularly serve as simulants to evaluate leachables from packaging materials.
• Oils: For the assessment of lipid-based formulations, oils such as corn oil may be appropriate.

Choosing suitable solvents not only facilitates accurate E&L testing but also supports compliance with the analytical evaluation threshold (AET) and dose-based threshold (DBT) calculations stipulated by the PQRI guidelines.

Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

Establishing the AET and DBT are pivotal steps in the E&L risk assessment process. The AET is a threshold below which leachables are unlikely to pose any safety concern. In contrast, the DBT, a new paradigm introduced by recent guidelines, takes into account the amount of substance that can be absorbed through a specific route of administration.

To calculate the AET, manufacturers should:

• Conduct a comprehensive literature review to identify known toxicological data for the substances under consideration.
• Integrate specific safety factors (usually 100) to adjust the AET based on the route of administration and population being examined.
• Use the formula provided in regulatory guidelines to derive the respective values under standardized conditions.

For the DBT, follow these steps:

• Establish the maximum daily dose for the drug.
• Integrate pharmacokinetic modeling data to relate the exposure to leachables.
• Utilize the excipient volume to correlate exposure levels to the DBT.

Both the AET and DBT must be documented meticulously during the validation process to substantiate claims made regarding the safety and efficacy of the drug product.

Container Closure Integrity (CCI) Testing

Container closure integrity (CCI) is a critical component in ensuring that drug products remain sterile and un-contaminated until administration. The USP recommends various methods for testing CCI, which are essential in validating the selection of both packaging systems and E&L simulants. Some widely utilized testing methods include:

• Vacuum Method: This method involves creating a vacuum and measuring the pressure to detect leaks, essential for glass containers.
• Microscope Analysis: Microscopic techniques can directly visualize breaches in the container seal.
• Mass Spectrometry: Advanced analytical methods will detect the presence of gases that indicate a breach in integrity.

Implementing appropriate CCI testing ensures that any data obtained during E&L studies will reflect the actual performance of the packaging system under specified conditions. Therefore, it becomes imperative to incorporate comprehensive CCI assessments as part of the overall packaging qualification strategy.

Single-Use Systems Validation

With increasing reliance on single-use systems in the pharmaceutical manufacturing landscape, robust validation practices are essential. Single-use systems (SUS) must be qualified to ensure they do not introduce risks of contamination or leachables into drug products. Validation processes should be clearly defined and executed following industry standards and regulations. The core components of SUS validation include:

• Design Qualification (DQ): Ensure that the design meets user requirements and applicable regulations.
• Installation Qualification (IQ): Confirm that the system is installed according to specifications and is suitable for the intended use.
• Operational Qualification (OQ): Validate that the SUS operates within the defined parameters.
• Performance Qualification (PQ): Assess the SUS performance under actual production conditions, including E&L testing.

Validation of SUS should be revisited regularly to ensure continued compliance and quality assurance throughout the product lifecycle.

Conclusion

Selecting realistic simulants for E&L testing in single-use systems is a multifaceted task that requires an understanding of pharmaceuticals, regulatory expectations, and analytical approaches. By systematically assessing the nature of the drug product, historical data, and applicable solvents, ensure that the chosen simulants will yield accurate and reliable results. Further, comprehension and calculation of the AET and DBT provide defensible justifications regarding product safety. Coupling these practices with meticulous CCI testing fortifies the integrity of the overall packaging qualification process.

As the global regulatory landscape continues to evolve, pharmaceutical professionals must stay informed and adaptable, ensuring approaches to E&L and CCI are aligned with best practices while promoting patient safety.